These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25692307)

  • 1. Inauhzin(c) inactivates c-Myc independently of p53.
    Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
    Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress.
    Zhang Q; Zhou X; Wu R; Mosley A; Zeng SX; Xing Z; Lu H
    Elife; 2014 Oct; 3():. PubMed ID: 25347121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global effect of inauhzin on human p53-responsive transcriptome.
    Liao JM; Zeng SX; Zhou X; Lu H
    PLoS One; 2012; 7(12):e52172. PubMed ID: 23284922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex.
    Liao JM; Zhou X; Gatignol A; Lu H
    Oncogene; 2014 Oct; 33(41):4916-23. PubMed ID: 24141778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.
    Bhattarai N; Wang J; Nguyen D; Yang X; Helmers L; Paruch J; Li L; Zhang Y; Meng K; Wang A; Jayawickramarajah J; Wang B; Zeng S; Lu H
    Theranostics; 2021; 11(14):7005-7017. PubMed ID: 34093867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Disubstituted Quindoline Derivatives Inhibiting Burkitt's Lymphoma Cell Proliferation by Impeding c-MYC Transcription.
    Liu HY; Chen AC; Yin QK; Li Z; Huang SM; Du G; He JH; Zan LP; Wang SK; Xu YH; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
    J Med Chem; 2017 Jul; 60(13):5438-5454. PubMed ID: 28603988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosomal protein S14 negatively regulates c-Myc activity.
    Zhou X; Hao Q; Liao JM; Liao P; Lu H
    J Biol Chem; 2013 Jul; 288(30):21793-801. PubMed ID: 23775087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth.
    Zhang Q; Ding D; Zeng SX; Ye QZ; Lu H
    PLoS One; 2012; 7(10):e46294. PubMed ID: 23115626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.
    Zhang Q; Zeng SX; Zhang Y; Zhang Y; Ding D; Ye Q; Meroueh SO; Lu H
    EMBO Mol Med; 2012 Apr; 4(4):298-312. PubMed ID: 22331558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activities of curcumin on human Burkitt's lymphoma.
    Wu Y; Chen Y; Xu J; Lu L
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):348-52. PubMed ID: 12408761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
    Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
    Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
    Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc inhibition negatively impacts lymphoma growth.
    Gomez-Curet I; Perkins RS; Bennett R; Feidler KL; Dunn SP; Krueger LJ
    J Pediatr Surg; 2006 Jan; 41(1):207-11; discussion 207-11. PubMed ID: 16410134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.
    Goudarzi KM; Nistér M; Lindström MS
    Cancer Biol Ther; 2014; 15(11):1499-514. PubMed ID: 25482947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.
    Zhang Y; Zhang Q; Zeng SX; Hao Q; Lu H
    Neoplasia; 2013 May; 15(5):523-34. PubMed ID: 23633924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
    Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
    Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a growth-inhibiting tripeptide, acetylGlu-Ser-GlyNH2 (Ac-ESG), on gene expression and cell cycle progression of two lymphoma cell lines.
    Liu Y; Reichelt WH; Luna L; Elgjo K; Reichelt KL
    Anticancer Res; 2003; 23(4):3159-65. PubMed ID: 12926049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
    Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
    Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.